Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing vonoprazan-based therapies for acid-related gastrointestinal diseases. Its commercial products include VOQUEZNA tablets, VOQUEZNA DUAL PAK, and VOQUEZNA TRIPLE PAK, which are marketed in the United States for conditions such as GERD and H. pylori infection.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueApproved VOQUEZNA-branded therapies sold in the U.S. for GERD and H. pylori-related indications.
Third-party pharmacy support and access programs that help patients obtain and stay on therapy.
Research, clinical, and regulatory work to expand vonoprazan into additional indications and formulations.
Customers
Phathom sells primarily into the U.S. prescription drug channel, with product flowing through wholesale distributors and select pharmacies before reaching patients, clinics, and institutions. Its commercial focus is on gastroenterologists, other high-prescribing healthcare providers, and select primary care physicians who treat GERD and H. pylori infection. Payer coverage and pharmacy access programs are important because they influence whether patients can start and continue therapy.
Buy finished product in the U.S. channel and distribute it to pharmacies and other outlets; they are the main revenue conduit.
Purchase VOQUEZNA products for dispensing to retail, institutional, clinic, and cash-pay patients.
High-prescribing specialists targeted for VOQUEZNA adoption in GERD and H. pylori treatment.
Selected PCPs who treat acid-related disorders and can expand prescribing beyond specialists.
Influence formulary placement, prior authorization, and patient out-of-pocket cost exposure.
Strategy
Phathom’s strategy is to expand adoption of VOQUEZNA by targeting high-prescribing gastroenterologists, selected primary care physicians, and patient access channels. It also seeks to broaden formulary coverage and support adherence through pharmacy services, while advancing vonoprazan into additional indications and formulations. The company’s commercial model depends on converting clinical awareness into repeat prescribing and maintaining access through payers and distributors.
Revenue depends on converting specialist awareness into sustained VOQUEZNA prescribing.
Coverage and prior authorization determine whether patients can start therapy and remain on treatment.
Additional indications and formulations can extend the product franchise beyond the initial launch set.
Geography
Phathom is centered in the United States, where it commercializes VOQUEZNA and conducts most of its operating activity. The company also has licensing economics tied to sales in the United States, Europe, and Canada through its Takeda agreement, but the disclosed commercial revenue base is U.S.-focused. Geography matters because access, reimbursement, and distribution are organized around the U.S. healthcare system.
Risks
Phathom is highly dependent on the commercial success of a small number of VOQUEZNA products, so demand, payer access, and prescriber adoption are central risks. It also faces typical pharmaceutical risks around product liability, manufacturing and supply chain dependence, clinical development uncertainty, and reliance on third parties for distribution and patient access. Because the company is still building its commercial base, financing needs and execution risk remain important business constraints.
- Dependence on VOQUEZNA commercial successImpact: CriticalLikelihood: Medium
The company currently depends entirely on a small set of approved products, especially VOQUEZNA for GERD.
Exposure: U.S. prescription demand and prescriber adoption
- Payer and reimbursement frictionImpact: HighLikelihood: High
Utilization management, step edits, and prior authorization can slow or block therapy initiation.
Exposure: National and regional health plans
- Customer concentrationImpact: HighLikelihood: Medium
A small number of wholesale and retail customers account for a large share of product sales.
Exposure: Three customers represented about 69% of product sales in 2025
- Product liability claimsImpact: HighLikelihood: Medium
Pharmaceutical products can generate litigation tied to safety, labeling, or use in patients.
Exposure: Commercial products and clinical candidates
- Third-party supply and service dependenceImpact: MediumLikelihood: Medium
Manufacturing, distribution, and patient access rely on external vendors and support providers.
Exposure
Accounting
Judgemental itemsReported product revenue is net of rebates, chargebacks, discounts, and other adjustments that require estimation.
Impact: Can materially change recognized revenue versus gross shipments
Royalties are payable on product sales and milestone payments depend on cumulative net sales thresholds.
Impact: Affects cost of revenue and long-term cash obligations
Launch-stage inventory and demand uncertainty can require write-downs.
Impact: Can increase cost of revenue and reduce reported gross margin
R&D costs for trials, CMC, consultants, and CROs are expensed as incurred.
Impact: Creates volatility tied to development activity
Similar listed companies
Publicly listed companies with a comparable business focus.
Verastem, Inc.
VSTM · Pharmaceutical Preparations
Lexicon Pharmaceuticals, Inc
LXRX · Pharmaceutical Preparations
Lexicon Pharmaceuticals is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing small-molecule medicines.
Ardelyx, Inc
ARDX · Pharmaceutical Preparations
Cumberland Pharmaceuticals Inc
CPIX · Pharmaceutical Preparations
Cytokinetics, Incorporated
CYTK · Pharmaceutical Preparations
Cytokinetics is a U.S.-based specialty biopharmaceutical company built around muscle biology and the mechanics of contractility.
Alnylam Pharmaceuticals, Inc
ALNY · Pharmaceutical Preparations
Last updated: 24/09/2026